Fiche publication
Date publication
juillet 2025
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Jiménez-Labaig P, Mohamed F, Tan NJI, Sanna I, El Bairi K, Khan SZ, Akhade A, Amaral T, Trapani D, Patel A, Harrington KJ
Lien Pubmed
Résumé
Anti-PD-(L)1 inhibitors have transformed cancer treatment. However, their high costs severely restrict their accessibility, especially in low- and middle-income countries (LMIC). Low-dose regimens, inferior to weigh-based or flat dosings, may help address this barrier. Our aim is to evaluate their dosing strategies, clinical outcomes, and potential cost savings.
Mots clés
Anti-PD1, Anti-PDL1, Cost-effectiveness, Financial toxicity, ICI, Immune-checkpoint inhibitor, Immunotherapy, Low-dose, Reduced dose, Ultra-low dose, Underdosing
Référence
Eur J Cancer. 2025 07 25;225:115564
